Upregulation of alveolar epithelial fluid transport after subacute lung injury in rats from bleomycin.
Alveolar epithelial fluid transport was studied 10 days after subacute lung injury had been induced with intratracheal bleomycin (0.75 U). An isosmolar Ringer lactate solution with 5% bovine serum albumin and 125I-labeled albumin as the alveolar protein tracer was instilled into the right lung; the rats were then studied for either 1 or 4 h. Alveolar fluid clearance was increased in bleomycin-injured rats by 110% over 1 h and by 75% over 4 h compared with control rats (P < 0.05). The increase in alveolar fluid clearance was partially inhibited by amiloride (10(-3) M). Alveolar fluid clearance decreased toward normal levels in rats that were studied 60 days after bleomycin instillation. Remarkably, the measured increase in net alveolar fluid clearance occurred in the presence of a significant increase in alveolar epithelial permeability to protein. Moreover, the increase in alveolar epithelial fluid clearance occurred even though the mRNA for the alpha-subunit of the epithelial sodium channel was decreased in alveolar epithelial type II cells isolated from these rats. In addition, 22Na uptake by isolated alveolar epithelial type II cells from rats treated with bleomycin demonstrated a 52% decrease in uptake compared with type II cells from control rats. Morphological results demonstrated a significant hyperplasia of alveolar type II epithelial cells 10 days after bleomycin injury. Thus, these results provide evidence that proliferation of alveolar epithelial type II cells after acute lung injury may upregulate the transport capacity of the alveolar epithelium, even though the expression of epithelial sodium channels is reduced and the uptake of 22Na per cell is also reduced. These results may have clinical relevance for the resolution of alveolar edema in the subacute phase of lung injury.
Folkesson
H G
HG
Cardiovascular Research Institute, University of California, San Francisco, California 94143-0130, USA.
Nitenberg
G
G
Oliver
B L
BL
Jayr
C
C
Albertine
K H
KH
Matthay
M A
MA
D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage / Q000633:toxicity*; D001826:Body Fluids / Q000502:physiology*; D001834:Body Water / Q000502:physiology; D002417:Cattle; D004847:Epithelial Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D007322:Instillation, Drug; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D011312:Pressure; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D011652:Pulmonary Circulation / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012710:Serum Albumin, Bovine; D012964:Sodium / Q000378:metabolism; D015222:Sodium Channels / Q000235:genetics / Q000378:metabolism
D015222:Sodium Channels; D001761:Bleomycin; D012710:Serum Albumin, Bovine; D012964:Sodium